期刊文献+

肿瘤异质性的影像学定量分析进展 被引量:7

Progress in Quantitative Analysis of Tumor Heterogeneity with Medical Images
下载PDF
导出
摘要 对影像学指标定量分析肿瘤异质性及其研究进展进行了综述.阐述了目前在肿瘤异质性定量分析研究中常用的影像学指标在正电子发射体层显像(PET)和磁共振成像(MRI)等不同成像技术中的应用,分析其在临床预测肿瘤患者放化疗疗效或生存期等方面的价值.临床研究结果显示,异质性参数与患者放化疗疗效、生存期等存在显著相关性,具有一定的临床参考价值.综合不同影像的异质性参数以寻求最优的参数来评价肿瘤异质性可完善量化分析肿瘤异质性的标准. The advancement in the field of tumor heterogeneity quantification and analysis with medical images were reviewed. Modern medical imaging techniques, such as positron emission tomography( PET) and magnetic resonance imaging( MRI),in quantifying the tumor heterogeneity were summarized,and clinical studies to correlate the features with tumor responses to radiochemotherapy and prognosis value were analyzed. Statistical analyses indicate that quantitative analysis of tumor heterogeneity is a strong predictor of treatment outcome and it has potential value for clinical application. Combining multimodality imaging parameters to optimize parameters of evaluation improves the quantitative analysis of tumor heterogeneity standard.
出处 《纳米技术与精密工程》 CAS CSCD 2014年第6期404-410,共7页 Nanotechnology and Precision Engineering
基金 国家自然科学基金资助项目(81171342) 教育部博士点新教师基金资助项目(20120032120073) 博士学科点专项科研基金资助项目(201202120014)
关键词 肿瘤 影像学 异质性 tumor imaging heterogeneity
  • 相关文献

参考文献6

二级参考文献35

  • 1Monika Dezortova,Pavel Taimr,Antonin Skoch,Julius Spicak,Milan Hajek.Etiology and functional status of liver cirrhosis by ^(31)P MR spectroscopy[J].World Journal of Gastroenterology,2005,11(44):6926-6931. 被引量:17
  • 2World Heahh Organization. Global tuberculosis control 2011[M]. Geneva: WHO, 2011: 10.
  • 3Houseni M, Chamroonrat W, Zhuang J, et al. Prognostic implication of Dual-Phase PET in adenocarcinoma of the lung[J]. J Nucl Med, 2010, 51(4): 535-542.
  • 4Goo JM, Im JG, Do KH, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases[J]. Radiology, 2000, 216(1): 117-121.
  • 5Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells[J]. J Nucl Med, 2002, 43: 1210-1217.
  • 6Yamamoto Y, Nishiyama Y, Ishikawa S, et al. Correlation of SFLT and SFDG uptake on PET with Ki-67 immunohisto- chemistry in non small lung cancer [J]. Eur J Nucl Med Mol Imaging, 2007, 34: 1610-1616.
  • 7Tian J, Yang X, Yu L, et al. A malticenter clinical trial on the diagnostic value of Dual-Tracer PET/CT in pulmonary lesions using 3'-Deoxy-3'-lSF-Fluorothymidine and SF-FDG [J]. J Nucl Med, 2008, 49(2): 186-194.
  • 8Halter G, Buck AK, Schirrmeister H, et al. [18F]3-deoxy-3'- fluorothymidine positron emission tomography: Alternative or diagnostic adjunct to 2-[ISF]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?[J]. J Thorac Cardiovasc Surg, 2004, 127: 1093-1099.
  • 9Lin PL, RodgersM, Smith L, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model [J]. Infect Immun, 2009, 77(10): 4631-4642.
  • 10Pugachev A, Ruan S, Carlin S, et al. Dependence of FDG uptake on tumor microenvironment [ J]. Int J Radiat Oncol Biol Phys, 2005, 62(2): 545-553.

共引文献81

同被引文献39

引证文献7

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部